The AGFiQ U.S. Market Neutral Anti-Beta Fund managed to return 18.50% over the past quarter -- and, no, it's not an inverse or levered inverse fund.
We like Canadian stocks for their relatively low valuations compared to US peers.
Let's review the charts and indicators.
While performance hasn't been mind blowing so far, psychedelics are where cannabis was a decade or so ago.
Sometimes it pays to look north of the border for companies with great dividends.
Forget crypto. Eight investment advisors select their favorite gold and silver plays for this year.
We have two new price targets.
Traders could go long CNQ at current levels and on available weakness.
Leading advisors pick four favorite cannabis purveyors, two marijuana ETFs and one ancillary tobacco segment firm.
Today's digital tools enable individual investors to quickly and easily acquire as much knowledge as large institutions.